These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16334621)

  • 1. Designer insulins regimens in clinical practice--pilot multicenter Indian study.
    Joshi SR; Kalra S; Badgandi M; Rao YS; Chawla M
    J Assoc Physicians India; 2005 Sep; 53():775-9. PubMed ID: 16334621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study.
    Fritsche A; Larbig M; Owens D; Häring HU;
    Diabetes Obes Metab; 2010 Feb; 12(2):115-23. PubMed ID: 20092584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials.
    Fonseca V; Davidson J; Home P; Snyder J; Jellinger P; Dyhr Toft A; Barnett A
    Curr Med Res Opin; 2010 Jul; 26(7):1621-8. PubMed ID: 20429817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.
    Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
    Cardiovasc Diabetol; 2009 Feb; 8():9. PubMed ID: 19220880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
    Liebl A; Prager R; Binz K; Kaiser M; Bergenstal R; Gallwitz B;
    Diabetes Obes Metab; 2009 Jan; 11(1):45-52. PubMed ID: 18643839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
    Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mid- and high-ratio premix insulin analogues: potential treatment options for patients with type 2 diabetes in need of greater postprandial blood glucose control.
    Christiansen JS; Liebl A; Davidson JA; Ligthelm RJ; Halimi S
    Diabetes Obes Metab; 2010 Feb; 12(2):105-14. PubMed ID: 19895637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
    Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
    Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes.
    Krzymień J; Kobli T; Nazar M
    Pol Arch Med Wewn; 2010 Nov; 120(11):444-50. PubMed ID: 21102380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: sub-analysis from the A(1)chieve(®) study.
    Hwang YC; Kang JG; Ahn KJ; Cha BS; Ihm SH; Lee S; Kim M; Lee BW
    Int J Clin Pract; 2014 Nov; 68(11):1338-44. PubMed ID: 25284679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus - a pilot study.
    Shanmugasundar G; Bhansali A; Walia R; Dutta P; Upreti V
    Indian J Med Res; 2012; 135(1):78-83. PubMed ID: 22382187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.